AMRN Amarin Corp - ADR

$AMRN Excerpts from today’s PR: “……. While the search for targeted Lp(a)-lowering therapies continues, VASCEPA/VAZKEPA is available today and has demonstrated cardiovascular event reduction on top of statin therapy across both high and low Lp(a) levels… Importantly, these findings remain highly relevant following the recent announcement that the Lp(a)HORIZON cardiovascular outcomes trial did not meet its primary endpoint despite substantial Lp(a) lowering, highlighting the need for therapies that have demonstrated cardiovascular event ….” My understanding: Vascepa can be administered for both low & high Lp(a) patients for a significant CVD RR.. Hopefully a BO sooner 👍

$AMRN I actually think that we are close to transaction. I like the change in language " in a timely and disciplined manner". The success with EMT2 might delay transaction just a bit, but they can structure CVR around it and off we go. It would be so sweet to hit a good buyout while market is bleeding red.

$AMRN Seems these results even more compelling than Reduce-It in 2018? End point here not met but that may be trial design? Most important is the 30% improvement in life span!!! For existing cancer patients!!! Reduce-It was a similar reduction in cardiovavular EVENTS. Seems too this is a much cleaner trial, no mineral oil controversy. Cancer a much higher degree and focus for patients and medical community, and BP, even though heart disease #1 killer. In short order after Reduce-It pps advanced from around $3 to mid mid twenties .. based on potential. Amarin a much more solid company financially now than then. This asset, at this pps, is a dream acquisition for a BP.

$AMRN PERFECT DAY FOR THE DELIVERY OF A CANCER DRUG 👊👊👊 I've got a barrage of posts coming breaking down various angles and thoughts on EMT2, stay tuned ⏳

$AMRN 🚨 TODAY: HIKMA ANTITRUST CASE DISMISSED FOLLOWING LAST WEEK'S AMARIN PATENT INFRINGEMENT DISMISSAL 🚨 I'm a little behind sharing this, but the overlapping timeline deserves attention. 📅 June 4: Supreme Court rules for Hikma on Amarin's infringement complaint. ⏳ July to Oct: FOUR joint extensions move the Delaware deadline from July 30 to Oct 27. 📄 Oct 20, 1:44 PM ET: Amarin, Mochida and Hikma file to dismiss the patent infringement case WITH PREJUDICE. 🔗 Oct 20, 3:01 PM ET: Just 77 minutes later, Hikma informs the NJ judge its ANTITRUST case against Amarin is resolved and submits a jointly signed dismissal. ✅ TODAY, Oct 27: The NJ court enters the antitrust dismissal WITH PREJUDICE. 📎 Screenshot attached below shows today's antitrust dismissal. 📌 Two opposing lawsuits resolved by agreement on Oct 20. The timing suggests a coordinated resolution, although financial terms remain undisclosed. Three other generic antitrust cases remain pending.

$AMRN The company is derisked after 4 years of Sarissa slashing the asset. You also dont need to finish the patent to sell the asset. Sarissa has a tax incentive to sell with hostile retail and a scheme under English law is needed. Where are we in the 8 step process for M&A? Amarin is past the cleanup stage. Cash-flow positive. Restructuring complete. $323.4M cash, no debt. Hikma settled. The remaining operational and legal items that were open when the Barclays process started are no longer open in the same way. Berg’s prepared remarks still state that the company continues to work closely with Barclays and that “these discussions and their potential outcomes will inform the timing, scale, and prioritization of future capital deployment activities, such as a share repurchase.” That is the language of a process that is still open and still gating the authorized buyback. On a standard process timeline that places the company past advisor retained, preparation, and outreach, and into the stage where indications of interest or early due diligence are the next visible steps. No binding bids or signed agreement have been disclosed. The process has also not been closed. The asset that can be sold is a secondary-market CVD franchise with a CRC option on a pending new-formulation patent. Ketchum has flagged upcoming AHA 2026 data on lipoprotein(a), an area of increasing interest in cardiovascular medicine. Any signal there sits on top of the existing Vascepa CVD franchise and is available to a buyer along with the rest of the package. U.S. Application No. 18/472,875 is pending with a Non-Final Office Action. It is transferable as-is. A buyer steps into the applicant’s shoes, can respond by the December 8 window or extend under 37 CFR 1.136(a), and can continue prosecution. The application does not need to be allowed or issued first. The EMT2 overall-survival data can be used by the buyer in that file. CRC liver metastases after resection is an unmet-need setting. Berg and Ketchum used that language on the call. Under FDA accelerated approval guidance a serious condition with an unmet need can qualify when the available data (here the secondary OS finding from EMT2) are reasonably likely to predict clinical benefit. A buyer that takes the patent and the data can pursue that path on the secondary indication without Amarin having to finish the work. The CVD business is the existing cash-generating franchise. The CRC option is the platform extension on the new formulation. Both transfer with the company. Under section 172 of the Companies Act 2006 the directors must act in the way they consider, in good faith, most likely to promote the success of the company for the benefit of the members. With the balance sheet cleaned, the major litigation resolved, cash flow positive, and a transferable patent application that needs little further effort, the remaining work is no longer operational cleanup. The continuing treatment of the $50M authorization as conditional on the Barclays discussions is the public evidence that the board is still treating a transaction path as the priority over immediate capital return. The patent does not need to be finished. The process does not need to be announced as a formal sale. The public record shows the company is de-risked, cash-rich, and still gating capital deployment on the outcome of the advisory work. That is the position from which bids for a secondary-market CVD platform with a CRC option are solicited.

$AMRN 🚨 MAJOR FRANCE DEVELOPMENT: VAZKEPA ENTERS OFFICIAL REIMBURSEMENT REVIEW 🚨 🎙️ JULY 29 Q2 CALL: Aaron Berg on France: “we have confidence in our partner to be able to do something there”, but said there was no update & cautioned it’s a lengthy process. 📅 OCT 7: France’s HAS Transparency Commission listed VAZKEPA for “EXAMENS: INSCRIPTION.” 🔎 INSCRIPTION = review for potential inclusion on France’s reimbursable medicines list. 🔥 TIMELINE: ✅ June 2025: Amarin identified revised France/Germany resubmission strategies. ✅ July 2026: Berg highlighted France and Recordati’s potential. ✅ October 2026: Official HAS examination agenda. ⏳ NEXT: HAS opinion (possibly Nov to Jan) ➡️ CEPS price talks ➡️ reimbursement listing ➡️ launch (2027 possible, not guaranteed). ⚠️ HAS gave a restricted favorable opinion in 2021, but France never launched. France is one of Amarin’s last ✌️ top 5 EU market left to open. AS ALWAYS, YOUR WELCOME 🫡

$AMRN in case you guys didn't see it, the GoodRx pricing has dropped for anyone interested in cash pay for Vascepa. You can now get a 3 month supply of brand Vascepa for$238 at Walmart.

$AMRN The monumental EMT2 results mean that Vascepa likely not only helps CRC but many types of cancer patients survival, (since the added life wasn't dependent upon delaying disease progress). In fact, most diseases likely could be helped with longer survival times and no unpleasant side effects by the kindest drug of all time. This opens up a huge opportunity in oral combo pills each with their own 20 year exclusivity. If the US decides to kibosh the new formulation, this provides another avenue to pierce US markets.

$AMRN Q3 is the turnaround quarter 🔥 ✅ First profitable quarter in 2+ years ✅ 4th straight quarter of positive cash flow ✅ $323M cash, ZERO debt (guiding ~$330M by year-end) ✅ Opex down 44% YoY; $70M cost program done ✅ Europe demand +68% YoY via Recordati; global partner demand +55% ✅ Still #1 in U.S. IPE at 47% share ✅ EU patent protection runs to 2039 Kickers: 🧬 EMT2 Phase 3 (ESMO late-breaker) shows potential for VASCEPA in colorectal cancer liver mets 🏦 Barclays still running the strategic review, with a "maximize shareholder value" mandate 📜 LR-EtEPA patent applications still pending in U.S. and EU. A grant on a new composition/formulation could give a next-gen EPA product that is not a generic substitute. Market cap is around $270M, below the cash pile. The floor is cash and the upside is takeout + IP. Holding long. 🚀 #AMRN #Biotech

$AMRN In Summary, Q3 vs. Q2 Statement of Operations: Amarin swung from a $7.65 million net loss in Q2 to a $245,000 net profit in Q3—a nearly $7.9 million quarter-over-quarter improvement. This turnaround in the bottom line came despite a 6.3% decline in revenue to $39.55 million, driven by significant cost reductions: SG&A fell 35.4%, and total operating expenses dropped 31.3%. The operating loss narrowed dramatically from $12.01 million to $2.36 million, showing that management’s tighter cost controls are having a meaningful impact. Revenue weakness remains a concern, and one profitable quarter does not yet establish a sustained turnaround, but Amarin is moving closer to consistent profitability. The next challenge is to stabilize revenue, maintain expense discipline, and turn this improved financial performance into lasting shareholder value.

$AMRN Four years of “creating, unlocking, and delivering shareholder value.” Early 2024 they put the $50 million repurchase authorization in writing with that exact language. Holt and Kostas called the stock undervalued and said the buyback showed the commitment. Management said on the call that approvals were on track and the buying would start shortly after. It has never been used. Cash and short-term investments were $314.6 million at June 30. The stock closed at $12.09. Market cap is about $249 million. The equity is under the cash. They have repeated the same shareholder-value language in the Recordati materials, the 2025 results, the earnings calls, and the October 25 EMT2 release. The chart shows the opposite. The stock is down more than 40 percent over the past year. The 52-week high was $20.57 in late October 2025. It has not held. Retail voted the equity plans down at the last two AGMs. The board and C-suite moved to cash compensation anyway. The $50 million authorization that was presented as proof of commitment is still unused while surplus cash sits in short-term Treasuries and they prepare to pay themselves in cash. On the next call they should be asked, in writing, what cash balance the board treats as minimum operating liquidity given current revenue, expenses, receivables, and inventory. They should state whether the unused $50 million is frozen because Barclays is running a process, and if so what disclosure or date starts the program. If that is not the reason, they should explain why Treasury interest is better for holders than buying shares under the cash. Rule 10b-18 is only a safe harbor for how you buy. It is not a reason to leave the authorization unused. Amarin is an English company. Section 172 of the Companies Act 2006 requires directors to promote the success of the company for the benefit of its members. The repeated claims have not been matched by capital return. The authorization announced with those claims is still sitting there. Ask them on the call.

$AMRN Typically oncology clinical trial takes about > 8 years from start to finish including FDA’s review and approval… As per the National Institute of Health (NIH) only <5% of oncology clinical trials are successful .. Means, if a pharmaceutical company undertakes a clinical trial, even after spending tons of $ and time, there’s no guarantee for success at the end.. But from EMT2 trial, any big pharma can see the success is guaranteed for OS, a critical and large unmet needs, as endpoint in oncology trials.. Hope AD is encashing this aspect asap for the benefit of shareholders as promised during takeover from previous management!! 🤞

$AMRN When signing up for the Q326 CC and the BOD and C suite pay themselves in cash click the link to submit these 8 questions. Don’t wait to be gaslit by a “barrage” of misinformation and narrative from other posters. When they don’t answer you will understand why but don’t swallow the narrative that follows as we lost 40% value this year alone and we head into 2027 and another year of opportunity cost piles up. Here is the full set of questions for the call: 1. What cash balance does the Board treat as the minimum required for operating liquidity, given current revenue, operating expenses, receivables, and the inventory still on the books? What amount above that minimum is surplus? 2. Is the unused $50 million repurchase authorization frozen because Barclays is running a live strategic process? If so, state that and identify the disclosure or date that would allow the program to start. If that is not the reason, explain why parking surplus cash in short-term Treasuries is a better use of capital for holders than executing the repurchase the company already has authority to complete. 3. Rule 10b-18 is only an execution safe harbor. It is not a reason to leave an authorized program unused. Amarin is an English company. Under section 172 of the Companies Act 2006, directors must act in the way they consider, in good faith, most likely to promote the success of the company for the benefit of the members. Why has the Board concluded that leaving the $50 million authorization unused, while the shares trade under cash, satisfies that duty? 4. At the current share price, deploying the full $50 million would retire roughly 20 percent of the ADS outstanding and raise cash per remaining share. Has the Board modeled that outcome, and if so, why has it rejected it in favor of Treasury interest? 5. Kostas is the chair and a former Sarissa partner. The August 27, 2026 13D/A shows the fund sold approximately 386,000 ADS around $14 and reduced its reported stake to 6.09 percent. Was any material non-public information regarding EMT2, the Hikma remand, the antitrust cases, or a strategic process known to the chair or to Sarissa before those sales? What information barrier, if any, exists between the chair and the fund that holds the remaining position? 6. In the 2023 proxy materials, ISP Fund LP was included in Sarissa’s group at 6,663,377 ordinary shares (approximately 333,000 ADS after the ratio change). Innoviva has stated it is unwinding its funding of ISP. Does the Board know whether any of the shares sold in August were ISP shares, whether those shares were transferred to Innoviva, or whether Innoviva now holds an Amarin position that should have been reported? If the Board does not know, why has it not asked? 7. Section 172 of the Companies Act 2006 requires directors to act in the way they consider, in good faith, most likely to promote the success of the company for the benefit of the members. The company has an unused $50 million repurchase authorization, cash and short-term investments of approximately $315 million, and shares trading below cash. It has also written off more than $75 million related to supply contracts and inventory under the current Board. What specific analysis has the Board performed to conclude that leaving the authorization unused and parking surplus cash in Treasuries promotes the success of the company for the benefit of the members? 8. Retail has now voted against the equity plans at two consecutive annual general meetings. The Board has continued to compensate itself and senior management in cash. Has the Board obtained independent advice on whether continuing that practice, while the repurchase authorization sits unused and the shares trade under cash, is consistent with its duties to the members under section 172? If so, will that advice be disclosed?

$AMRN It's been a.while since we had a bump up in pps after earnings report. Hope this is a new beginning for Amarin 2.0

$AMRN hey look on the bright side, we may be the first people in history to invest in a drug that reduces risk of heart attack and death by cancer by 30% and somehow still lost our hard earned money!

$AMRN I realize that the two examples shown in the following slide are from two different patient populations and the interpretation is probably coincidental, but I noticed a similar separation pattern in the KM curves for "All-Cause Mortality" (REDUCE-IT USA) vs. Overall Survival" in EMT-2. Note that in both trials the curves begin to separate at about 18-24 months. It's like Apples to Oranges, but I found it interesting. Perhaps latter studies can tie the two together after we LONGs get some LOVE from our long suffering!

$AMRN Am eagerly waiting for the Management to share new insights in AHA, Chicago.. Hopefully looking for vauable insights before market opens tomorrow (on Monday) to increase the shareholders value… By now, longs must be aware that only Vascepa cuts CVD risks besides statin and almost all other medications to reduce biomarkers didn’t show any effects or benefits for CVD RR.. including the latest NVS HORIZON trial !!! Hopefully one of the big pharmas make a BO deal ASAP…🤞 Patiently waiting for good news from Amarin…

$AMRN Very po'd at Amarin again. Very positive news. So they put out a pr on Sunday morning. NO follow-up on Monday to get this news out with more mainstream outlets. Really is unbelievable.

$AMRN $AMRN 🔥 EMT2 Phase III (ESMO LBA30): Despite missing its primary PFS endpoint (HR 0.89; p=0.33), Vascepa delivered an encouraging overall-survival signal in 418 colorectal cancer patients following liver metastasis surgery. Five-year survival was 62.0% versus 45.1% on placebo—a remarkable 16.9-percentage-point difference! OS HR 0.68 (95% CI 0.48–0.96; nominal p=0.030), suggesting approximately 32% lower hazard of death. Overall survival is oncology’s gold-standard endpoint because extending life matters most. Although the failed primary endpoint limits formal statistical conclusions, these prespecified secondary findings deserve serious attention and further investigation. Vascepa’s potential beyond cardiovascular medicine may be more significant than previously appreciated!